iRadimedIRMD
IRMD
About: iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Employees: 160
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
37% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 51
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
2% more funds holding
Funds holding: 165 [Q4 2024] → 168 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.06% less ownership
Funds ownership: 54.78% [Q4 2024] → 54.73% (-0.06%) [Q1 2025]
4% less capital invested
Capital invested by funds: $382M [Q4 2024] → $365M (-$16.5M) [Q1 2025]
97% less call options, than puts
Call options by funds: $5K | Put options by funds: $167K
Research analyst outlook
We haven’t received any recent analyst ratings for IRMD.
Financial journalist opinion
Negative
Zacks Investment Research
3 days ago
New Strong Sell Stocks for June 12th
LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.
Neutral
GlobeNewsWire
2 weeks ago
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005.
Neutral
Seeking Alpha
1 month ago
IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
IRadimed (IRMD) Lags Q1 Earnings Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION Announces First Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024. Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.
Neutral
GlobeNewsWire
1 month ago
CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows:
Neutral
GlobeNewsWire
1 month ago
IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
Positive
Seeking Alpha
2 months ago
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space
IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets.
Neutral
GlobeNewsWire
3 months ago
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference.
Neutral
Seeking Alpha
4 months ago
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Charts implemented using Lightweight Charts™